Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: BMcV who wrote (14966)	12/27/2004 12:27:25 PM
From: Biomaven	Respond to of 52153

People have looked at the aspirin effect in some of the studies. It adds another variable, so it makes things that much more confusing. There's an additional variable - ultra low dose aspirin vs. regular dose as well. One thing that does emerge is that specifically ibuprofen plus aspirin is NOT a good idea, for reasons that are unclear. Peter

To: BMcV who wrote (14966)	12/27/2004 5:06:12 PM
From: software salesperson	Read Replies (1) \| Respond to of 52153

here's an idea about aleve: i don't believe the results. consider that the implicated aleve dose is 220 mg. twice/daily. before aleve was sold otc, naprosyn was sold at doses of 250/375/500 twice/daily, with 375 mg. being, i believe, the standard dose. naprosyn was sold from at least 1976 to 1999, when the cox-2 inhibitors came on the market. during that time, many billions of naprosyn were sold.there had to be a lot of people who were taking naprosyn alone. if there truly were a cardio issue with naprosyn, it would likely have shown up a long time ago. so, extremely unlikely that the lower dose product, i.e. aleve, has an issue. sales